This week's issue of The Savvy Diabetic:
3D printed islet transplantation
Abvance therapy funded for next-generation glucagon analogs/therapies
Glucotrack's CBGM Implant Technology
The AX-4 Space Mission Study Glucose Metabolism and Microgravity
Research: Implementing aid systems, specifying FDA interoperability
3D printing will enable long-term islet transplantation in type I diabetes on June 30, 2025 by InsidePrecisionMedicine.com.
Researchers have developed a new method for 3D printed functional human pancreatic islets that can maintain a strong insulin response for up to three weeks. New bioinks derived from human pancreatic tissues allow you to unlock innovative and minimal invasive approaches to islet transplantationIt may overcome some of the key challenges facing the development of type 1 cell therapy Diabetes.
“This was one of the first studies to use real human islets instead of animal cells in bioprints, and the results are extremely promising. This means we are approaching creating ready-made treatments for diabetes that can one day eliminate the need for insulin injections. Congress 2025.
A new method developed by Perrier and colleagues demonstrates the early promise that transplanted islets can continue to function. “Our goal was to replicate the natural environment of the pancreas so that the implanted cells survive and function better,” Perrier said. “We used special bio-inks that mimic the pancreatic support structures, providing the islets with the oxygen and nutrients they need to thrive.”
Innovation lies in the composition of 3D printed bioinks. The extracellular matrix (ECM) is known to play an important role in the survival and function of pancreatic islets. However, current methods for islet transplantation to separate cells remove it. The researchers have developed a gentle, detergent-free method to obtain soluble ECM powders from the human pancreas, which retain important components that support pancreatic survival and function.
Read more: 3D printing may allow long-term islet transplantation in type I diabetes
Abvance secured seed funding for StartupHealth.com's safer diabetes management Bynicole Kinsey on July 1, 2025.
Abvance's Discovery Platform is based on basic research conducted at Vanderbilt University. This includes the work of Dr. Alan Cherrington. Abvance is developing co-forming with practical and predictable glucagon analogs, including glucagon analogs, designed to seamlessly integrate into the latest treatment regimens for diabetic patients.
Edward Ruskin was appointed CEO, bringing him extensive experience in biotechnology and health technologies focused on diabetes. Ruskin was previously a co-founder of Beta Bionics and played a key role in advancing the first bihormonal bionic pancreas. Dr. David Maggs, co-founder of Abvance, will serve as Chief Medical Officer.
Abvance's glucagon analogues are designed for flexible use, whether in a fixed ratio combination with insulin collected at mealtime or for other new applications. The company focuses on products with a pharmacological profile tailored to alleviate hypoglycemia without destroying the underlying diabetes therapy. Its initial focus lies in the population demanding insulin. This population remains a sustained barrier for hypoglycemia to achieve close glycemic control and maintain quality of life.
read more:
Glucotrack describes three years of CBGM implant technology by Sean Hooley of Drugdeliverybusiness.com on July 22, 2025.
Glucotrack's devices do not have external on-body components. The company designed a 3-year continuous, accurate blood glucose monitoring to provide a more convenient and uninterrupted solution. Unlike traditional CGM, which measures glucose in interstitial fluids, CBGM measures glucose levels directly from the blood. It is usually intended to provide real-time measurements without delay times associated with interstitial glucose measurements.
The implant is 5 centimeters within the subclavian vein. Glucotrack's active implantable device features a small battery and electronics implanted just below the skin in the chest. Mark Tapsac, Chief Science Officer of Mark Tapsac, explained that the implant location is not the main container, but that real-time glucose levels can be measured as pulsating blood flows through the tip of the sensor. The device, which is about the size of a USB drive, weighs only 6.5 grams.
According to Tapsak, Glucotrack's devices address specific challenges associated with working in the interstitial space, such as delay times such as measurements, compression rates, and more. “That's not true,” Tapsac said of the company's implant location. “It's a protected space.”
Read more: Glucotrack explains three years of CBGM implant technology
Shubhanshu Shukla's space mission can rewrite the rules of diabetes care. July 2, 2025, by Daphne Clarance from Indiatoday.in.
An important highlight of the AX-4 mission is a research project called Suite Ride, designed to study how glucose metabolism is affected by microgravity. The ultimate goal is to make it safe for diabetics to live and work in space.
“Sweetride is investigating how spatial environment affects glucose metabolism in the human body, which will improve our understanding of diabetes and other metabolic diseases that affect blood glucose regulation.” Research collaborator behind the project, Burjeel Holdings, partnered with Axiom Space to investigate the performance of continuous glucose monitors (CGMS) and insulin in space.
“One or more astronauts wear CGMs throughout the entire mission. Measurements are monitored continuously and data are collected. Insulin pens were sent during flight, but astronauts are not using them. They are testing the feasibility and stability of insulin in a space environment.
Read more: Shubhanshu Shukla's Space Mission Can Rewrite Diabetes Care Rules
Practical Considerations and Implementation of an Automated Insulin Delivery System by Laurel H. Messer et al., published on July 1, 2025 in the Journal of Diabetes Science and Technology.
Automated insulin delivery techniques have inevitably evolved considering how diabetic people (PWDs) and HCPS use the devices. An ideal aid system requires no user input beyond placement and deletion. As we tackle this goal, broader concepts of how humans interact with machines will be adapted to the aid paradigm.
Read more: Practical considerations and implementation of automated insulin delivery systems
Designation of FDA Interoperability – Creative Options for Diabetes and Pumping Company People: Regulation, Technology, Commercial Perspectives by David C. Klonoff et al, and published in the Journal of Diabetes Science and Technology on September 10, 2024.
In the future, pump users may become increasingly knowledgeable and demanded about the capabilities of insulin delivery that can be achieved with specific IAGC algorithms. Unlocking the possibility of using interoperable blood glucose controllers (IAGCs) in AID systems allows insulin pump manufacturers to offer products that increase their flexibility in managing diabetes.
Future: As aid products become more and more established in both type 1 and type 2 diabetes, we expect two trends to affect the aid market.
First, ACE Pumps emits integration options with major ICGMs to create many aid systems, with manufacturers looking for new differentiated, interoperable features. Second, artificial intelligence is becoming increasingly established in IAGCS, which increases their appeal and the likelihood of consumption.
Both trends are expected to lead diabetic people to request aid systems that include specific ACE pumps integrated with specific IAGC software. This demand creates commercial incentives for ACE pump companies to address regulatory, technical and commercial barriers to launching aid systems that integrate multiple priority software algorithms.
Read more: Specifying FDA Interoperability – Creating Creation Options for Diabetes and Pumping Company People